281 completed, 60 unknown, 32 terminated, 23 recruiting. 433 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 433 | Completed 281, Unknown 60, Terminated 32, Recruiting 23, Withdrawn 19, Not yet recruiting 12, Active not recruiting 4, Enrolling by invitation 1, Suspended 1 |
Follow Depressive Disorder: new trials by email Literature Review of Depressive Disorder trials Research Report on Depressive Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder bupropion hydrobromide, Placebo - Major Depressive Disorder | Phase 4 | Not yet recruiting | Bausch Health Americas, Inc. | 246 | 2027-07-01 | 2026-09-29 |
| Stony Brook Medicine Anti-Inflammatory Trial Celecoxib, Minocycline - Major Depressive Disorder | Phase 4 | Not yet recruiting | Stony Brook University | 42 | 2027-06-01 | 2026-04-23 |
| Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts Ketamine hydrochloride infusion - Major Depressive Disorder (MDD) | Phase 4 | Not yet recruiting | New York State Psychiatric Institute | 12 | 2026-10-01 | 2026-08-03 |
| Biomarker-Guided Antidepressant Selection TMS, Ketamine - Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD) | Phase 4 | Recruiting | Weill Medical College of Cornell University | 27 | 2026-08-10 | 2026-11-06 |
| Intranasal Esketamine-dexmedetomidine Combination and Postpartum Depression Esketamine-dexmedetomidine combination, Placebo - Parturients, Depressive Symptoms | Phase 4 | Not yet recruiting | Peking University First Hospital | 164 | 2026-06-01 | 2026-06-15 |
| Efficacy and Safety of Daridorexant in Patients With Major Depressive Disorder and Insomnia Daridorexant 50 mg, Placebo - Insomnia, Major Depressive Disorder | Phase 4 | Not yet recruiting | Institut d'Investigació Biomèdica de Bellvitge | 134 | 2026-04-01 | 2026-04-29 |
| RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE) Vortioxetine, Cariprazine (Augmentation Phase) - Unipolar Depression, Bipolar Depression | Phase 4 | Recruiting | Mayo Clinic | 120 | 2026-02-17 | 2026-06-22 |
| Esketamine With or Without Integration Therapy for Treatment-Resistant Depression Esketamine hydrochloride (intranasal), Integration Therapy - Treatment-resistant Depression (TRD) | Phase 4 | Recruiting | University of Puerto Rico | 20 | 2026-02-01 | 2026-01-27 |
| Treatment of Anaemia After Caesarean With Intravenous Versus Oral Iron and Postpartum Depression Ferric carboxymaltose IV, TIMOFÉROL® - Postpartum Depression (PPD) | Phase 4 | Recruiting | Assistance Publique - Hôpitaux de Paris | 2860 | 2025-10-22 | 2026-09-21 |
| Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity Semaglutide Injectable Product, Placebo - Major Depressive Disorder | Phase 4 | Recruiting | Nordsjaellands Hospital | 116 | 2025-09-11 | 2026-02-06 |
| A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Valbenazine - Schizophrenia, Schizoaffective Disorder | Phase 4 | Recruiting | Neurocrine Biosciences | 100 | 2025-08-29 | 2026-09-18 |
| Disposition Kinetics of Dolutegravir Among People Living With HIV With Major Depression in Nigeria Fluoxetine, Cognitive-behavioral therapy - Depression, HIV | Phase 4 | Not yet recruiting | University of Ibadan | 168 | 2025-08-14 | 2025-08-08 |
| Algorithm Guided Treatment Versus Treatment as Usual (TAU) for Patients With Treatment Resistant Depression Algorithm guided treatment (AGT), Treatment as usual (TAU) - Treatment Resistant Depression (TRD) | Phase 4 | Recruiting | Aalborg University Hospital | 80 | 2025-08-13 | 2026-04-27 |
| The Role of mGluR5 in CBT-I Cognitive Behavioral Therapy for Insomnia, PET Scan with [11C]ABP688 - Major Depressive Disorder (MDD) | Phase 4 | Recruiting | Stony Brook University | 42 | 2025-08-01 | 2026-11-10 |
| Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression（SMART-I) Sertraline, Agomelatine, Aripiprazole - Major Depressive Disorder (MDD) | Phase 4 | Not yet recruiting | Xinyu Zhou | 400 | 2025-06-20 | 2025-06-10 |
| A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression Esketamine 56 mg, Esketamine 84 mg - Depressive Disorder, Treatment-Resistant | Phase 4 | Completed | Janssen Korea, Ltd., Korea | 47 | 2025-06-09 | 2026-08-03 |
| Allopregnanolone and Dynamic GABA-A Receptor Plasticity in Selective Serotonin Reuptake Inhibitor Responsive Premenstrual Dysphoric Disorder sertraline 50 mg daily, Placebo Oral Tablet - Premenstrual Dysphoric Disorder (PMDD) | Phase 4 | Recruiting | Johns Hopkins University | 288 | 2025-05-14 | 2026-05-07 |
| Effective of Transcranial Magnetic Stimulation (TMS) vs Treatment as Usual for First-Episode Depression in Adults Transcranial magnetic stimulation, Antidepressant - Major Depressive Disorder | Phase 4 | Not yet recruiting | Sultan Qaboos University | 120 | 2025-01-01 | 2024-10-28 |
| A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study on the Treatment of Depression with Jieyu Chufan Capsules Jieyu Chufan Capsules, Jieyu Chufan Capsules simulant - Major Depressive Disorder (MDD) | Phase 4 | Not yet recruiting | Central South University | 480 | 2024-12-22 | 2024-12-27 |
| Precision Care for Major Depressive Disorder Pramipexole, Methylphenidate, Phenelzine - Major Depressive Disorder, Depression | Phase 4 | Enrolling by invitation | University of California, San Francisco | 150 | 2024-11-12 | 2025-09-05 |
Showing 20 of 433. Sign in to see all of them.
Depressive Disorder, Major (333) · Depression (164) · Depressive Disorder, Treatment-Resistant (34) · Bipolar Disorder (26) · Dysthymic Disorder (20) · Anxiety Disorders (18) · Depression, Postpartum (14) · Mood Disorders (14) · Cognitive Dysfunction (7) · Premenstrual Dysphoric Disorder (7) · Psychotic Disorders (7) · Schizophrenia (7) · Sleep Initiation and Maintenance Disorders (7) · Suicidal Ideation (7)
Mental Disorders (427) · Mood Disorders (419) · Behavior (169) · Behavioral Symptoms (165) · Pathological Conditions, Signs and Symptoms (39) · Nervous System Diseases (38) · Bipolar and Related Disorders (26) · Signs and Symptoms (23) · Neurologic Manifestations (21) · Pathologic Processes (18) · Central Nervous System Diseases (17) · Urogenital Diseases (17) · Female Urogenital Diseases and Pregnancy Complications (15) · Brain Diseases (14)
Escitalopram (81) · Duloxetine Hydrochloride (36) · Ketamine (35) · Sertraline (34) · Bupropion (32) · Venlafaxine Hydrochloride (24) · Fluoxetine (20) · Paroxetine (20) · Citalopram (17) · Vortioxetine (14) · Aripiprazole (13) · Mirtazapine (12) · Dexetimide (11) · Esketamine (11) · Desvenlafaxine Succinate (9)
New York State Psychiatric Institute (36) · Massachusetts General Hospital (16) · University of California, Los Angeles (16) · Eli Lilly and Company (14) · University of Pittsburgh (10) · Shanghai Mental Health Center (8) · Emory University (7) · Forest Laboratories (6) · Sheba Medical Center (6) · University of Texas Southwestern Medical Center (6) · Weill Medical College of Cornell University (6) · H. Lundbeck A/S (5) · Mclean Hospital (5) · Medical University of Vienna (5) · National Institute of Mental Health (NIMH) (5)
United States (235) · Canada (35) · China (24) · South Korea (17) · France (13) · Italy (12) · Israel (11) · Taiwan (11) · Germany (10) · Spain (9) · Australia (8) · Denmark (7) · Netherlands (6) · Russia (6) · Sweden (6)
Bret Rutherford, MD (5) · Ian A Cook, MD (5) · David J. Hellerstein, MD (4) · Warren D Taylor, MD, MHSc (4) · Amit Anand, MD (3) · Bret R Rutherford, MD (3) · Helen Lavretsky, M.D. (3) · Jonathan W. Stewart, M.D. (3) · Maurizio Fava, MD (3) · Perry F Renshaw, MD, PhD, MBA (3) · Rajnish Mago, MD (3)
PMID 17074942, PMID 23380715, PMID 25758058, PMID 25980552, PMID 26709542, PMID 26803397, PMID 27733282, PMID 29608461, PMID 34183490, PMID 35592490, PMID 36999619, PMID 39428602, PMID 42214294, PMID 10082232, PMID 10686270, PMID 11806859, PMID 12813115, PMID 1308374, PMID 1438661, PMID 14627997, PMID 14639062, PMID 15729083, PMID 15800181, PMID 15939837, PMID 16086624, PMID 16390886, PMID 16426099, PMID 16457894, PMID 16540613, PMID 16551710, PMID 16554525, PMID 16554526, PMID 16566612, PMID 16566901, PMID 16636629, PMID 16642436, PMID 16690084, PMID 16754414, PMID 16816220, PMID 16824617, PMID 16946176, PMID 16946177, PMID 16946178, PMID 16974189, PMID 17015814, PMID 17091129, PMID 17195602, PMID 17302619, PMID 17389902, PMID 17431740
2018 (2), 2019 (2), K23MH076049 (2), 1RC1MH088438 (1), 2004 (1), 2005 (1), 2008 (1), 2016 (1), 2023 (1), 2025 (1), K12HD001441 (1), K23MH064196 (1), K23MH067060 (1), K23MH067710 (1), K23MH067894 (1)